Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
32
CHE Quote, Financials, Valuation and Earnings
Last price:
$522.34
Seasonality move
:
7.28%
Day range:
$520.00 - $526.21
52-week range:
$516.91 - $654.62
Dividend yield:
0.34%
P/E ratio:
26.44x
P/S ratio:
3.36x
P/B ratio:
6.34x
Volume:
205.3K
Avg. volume:
96.4K
1-year change:
-10.1%
Market cap:
$7.8B
Revenue:
$2.3B
EPS (TTM):
$19.79
Analysts' Opinion
-
Consensus RatingChemed has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Chemed has an estimated upside of 26.86% from its current price of $523.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $523.16.
Fair Value
-
According to the consensus of 0 analysts, Chemed has 26.86% upside to fair value with a price target of -- per share.
CHE vs. S&P 500
-
Over the past 5 trading days, Chemed has underperformed the S&P 500 by -2.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Chemed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chemed has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Chemed reported revenues of $606.2M.
Earnings Growth
-
Chemed has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Chemed reported earnings per share of $5.00.
Enterprise value:
7.6B
EV / Invested capital:
6.15x
Price / LTM sales:
3.36x
EV / EBIT:
19.16x
EV / Revenue:
3.20x
PEG ratio (5yr expected):
1.17x
EV / Free cash flow:
24.31x
Price / Operating cash flow:
25.53x
Enterprise value / EBITDA:
16.55x
Gross Profit (TTM):
$847.8M
Return On Assets:
17.83%
Net Income Margin (TTM):
12.69%
Return On Equity:
26.22%
Return On Invested Capital:
26.15%
Operating Margin:
15.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1B | $2.2B | $2.4B | $564.5M | $606.2M | |
| Gross Profit | $772.7M | $768.3M | $847.8M | $202.2M | $210M | |
| Operating Income | $361.2M | $315.7M | $368.9M | $86.9M | $92.2M | |
| EBITDA | $405.8M | $381.5M | $459.3M | $109.1M | $117.2M | |
| Diluted EPS | $17.21 | $16.15 | $19.79 | $4.93 | $5.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $270.6M | $200.6M | $198.9M | $394.5M | $490.4M | |
| Total Assets | $1.4B | $1.3B | $1.4B | $1.6B | $1.8B | |
| Current Liabilities | $329.2M | $286.1M | $298.2M | $297.2M | $264.8M | |
| Total Liabilities | $565.5M | $538.4M | $634.8M | $542.8M | $533.7M | |
| Total Equity | $801.4M | $779.7M | $721.4M | $1B | $1.2B | |
| Total Debt | -- | -- | $100.9M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $273.3M | $321.9M | $361.1M | $28.9M | $90.5M | |
| Cash From Investing | -$54M | -$68.5M | -$143.1M | -$15.4M | -$18.5M | |
| Cash From Financing | -$240.3M | -$88.1M | -$152.8M | -$263K | -$56.5M | |
| Free Cash Flow | $220M | $258.6M | $312.6M | $17.3M | $77M | |
CHE
Sector
Market Cap
$7.8B
$43.9M
Price % of 52-Week High
79.92%
45.73%
Dividend Yield
0.34%
0%
Shareholder Yield
2.42%
-0.74%
1-Year Price Total Return
-10.1%
-29.11%
Beta (5-Year)
0.460
0.772
Dividend yield:
0.34%
Annualized payout:
$1.56
Payout ratio:
8.5%
Growth streak:
15 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$534.58
200-day SMA
Sell
Level
$575.11
Bollinger Bands (100)
Sell
Level
551.27 - 593.23
Chaikin Money Flow
Buy
Level
48.4M
20-day SMA
Sell
Level
$552.16
Relative Strength Index (RSI14)
Sell
Level
30.95
ADX Line
Buy
Level
7.14
Williams %R
Buy
Level
-88.758
50-day SMA
Sell
Level
$564.17
MACD (12, 26)
Sell
Level
-11.11
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
41.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.6621)
Buy
CA Score
(Annual)
Level (1.6509)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-2.4421)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
Stock Forecast FAQ
In the current month, CHE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CHE average analyst price target in the past 3 months is --.
-
Where Will Chemed Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chemed share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Chemed?
Analysts are divided on their view about Chemed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chemed is a Sell and believe this share price will drop from its current level to --.
-
What Is Chemed's Price Target?
The price target for Chemed over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CHE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chemed is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CHE?
You can purchase shares of Chemed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chemed shares.
-
What Is The Chemed Share Price Today?
Chemed was last trading at $522.34 per share. This represents the most recent stock quote for Chemed. Yesterday, Chemed closed at $523.16 per share.
-
How To Buy Chemed Stock Online?
In order to purchase Chemed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 7.8% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 11.48% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 2.74% over the past day.
